Abu Dhabi, UAE — In a landmark move for medical innovation, Elon Musk’s neurotechnology firm Neuralink has launched its first international clinical trial in Abu Dhabi, marking the company’s expansion into the Middle East. The study, titled UAE-PRIME, is being conducted in collaboration with Cleveland Clinic Abu Dhabi and the Department of Health – Abu Dhabi.
The trial is focused on evaluating brain-computer interface (BCI) implants for individuals suffering from severe motor and speech impairments, including conditions such as amyotrophic lateral sclerosis (ALS) and spinal cord injuries. Participants in the trial will undergo a surgical implant of Neuralink’s BCI device, which aims to allow users to control external devices using only their thoughts.
“This trial represents a critical step forward in redefining what’s possible in neurorehabilitation,” said a representative from Cleveland Clinic Abu Dhabi. “The potential to restore communication and mobility to patients through a brain implant is no longer science fiction—it’s happening here in the UAE.”
The UAE-PRIME trial aligns with Abu Dhabi’s ambitious goals to become a global center for healthcare innovationand medical research. It is part of the emirate’s broader $25.6 billion health cluster strategy, which includes strategic partnerships and investments to attract cutting-edge biotech and medtech companies to the region.
Neuralink’s presence in Abu Dhabi also reflects the UAE’s growing reputation as a testbed for transformative technologies. The trial will not only support local and regional patients but will also contribute valuable data to the global research community in the field of neural interfaces.
This development positions the UAE at the forefront of next-generation medical technology, reinforcing its role as a key player in shaping the future of healthcare and neuroscience.
